All News

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

During an afternoon AMCP 2026 session, experts called for integrated clinical and payer care models to combat rising metabolic disease prevalence, costs, and complexity.

A July 2026 advisory meeting will evaluate whether broader compounding access to peptides is justified despite concerns around safety, efficacy, and limited clinical evidence.

The expiration of subsides for health coverage starting in 2026 has left millions facing higher premiums with little notice.

An AMCP 2026 session emphasized the need to shift to workflow-integrated AI by 2030 and stressed the importance of governance, trust, and scalable implementation.

Todd Doyle, MD, of OneOncology, warns that commercial payers lag on updating bundled codes, which has slashed radiation oncology revenue and risks community cancer access in 2026.

Real-world EHR study shows PREVENT equations deliver reliable CVD risk prediction despite missing data, guiding smarter outreach and recalibration.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

The increased costs of premiums after the expiration of enhanced subsidies have led to an increased percentage of those not able to make their payments.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

Rapid advances in precision oncology are exposing gaps in testing, treatment access, and care delivery, challenging managed care to keep pace.

Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among Medicare patients, whereas comorbid DED did not affect glaucoma adherence.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

New results show that reproxalap did not cause any serious treatment-related adverse events in patients living with dry eye disease.

A large cohort study across UK Biobank and All of Us finds RBM20 variants contribute to arrhythmogenic dilated cardiomyopathy.

Two posters presented at AMCP 2026 suggest improving GLP-1 adherence and access may enhance outcomes and lower obesity-related costs.

CHECK-US data show chronic hand eczema is driven by multiple triggers and linked to moderate disease severity and significant quality-of-life burden.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

Focal segmental glomerulosclerosis can lead to protein leakage in urine and hypertension; the condition is not considered curable at present, only manageable.

The global prevalence of MASLD was 16.1% as recently as 2023, with many individuals being asymptomatic and carrying a major risk of future complications.

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.